Registry study for pregnancy exposure to MenQuadfi vaccine
Part of Infections clinical trials.
This is an observational registry that collects information about pregnant people and their babies when MenQuadfi® (a meningitis vaccine) was given during pregnancy or shortly before pregnancy. It helps researchers understand what happens to women and offspring after this vaccine exposure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or the pregnancy) must be in the United States or its territories.
- The pregnancy must involve exposure to MenQuadfi® during pregnancy or within 30 days before your last menstrual period (LMP).
- Your vaccine exposure must be reported to the pregnancy registry with enough details to confirm timing.
- The report must include the vaccine name (MenQuadfi® or another meningococcal vaccine brand/generic).
- This registry uses post-marketing reports only, not people enrolled from other clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine to protect babies and toddlers from meningitis (a serious infection of the brain and spinal cord). It checks how well the vaccine works and how safe it is in young children.
This study monitors pregnant individuals who received the Penbraya vaccine to check for any safety concerns. It helps ensure the vaccine is safe for you and your baby.
This study watches for any side effects or health changes after you receive the MenQuadfi vaccine, which protects against four types of meningococcal bacteria. Your doctor will follow up with you to make sure the vaccine is safe and working well.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This registry collects information about people who were pregnant and exposed to the Dengvaxia vaccine during pregnancy, to better understand outcomes after that exposure. It may help future mothers and clinicians by building a clearer safety and health record over time.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
Hear when a new Meningococcal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.